Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin

Journal of the National Cancer Institute

Volumn 92, Issue 4, 2000, Pages 328-332

  Ross, Ronald K ^a   Paganini Hill, Annlia ^a   Wan, Peggy C ^a   Pike, Malcolm C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MITOSIS SPINDLE; POPULATION RESEARCH; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SUBSTITUTION THERAPY;

EID: 0034673201     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.4.328     Document Type: Article

References (25)

1. Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol 1985;65: 441-6.
2. Smith DC, Prentice R. Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-7.
3. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-70.
4. Hemminki E, Kennedy DL, Baum C, McKinlay SM. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86. Am J Public Health 1988;78: 1479-81.
5. Henderson BE, Ross RK, Lobo RA, Pike MC, Mack TM. Re-evaluating the role of progestogen therapy after the menopause. Fert Steril 1988;49(5 Suppl 2):9S-15S.
6. Pike MC, Peters RK. Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-6.
7. Ross RK, Paganini-Hill A, Roy S, Chao A, Henderson BE. Past and present preferred prescribing practices of hormone replacement therapy among Los Angeles gynecologists: possible implications for public health. Am J Public Health 1988;78:516-9.
8. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
9. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.
10. Persson I, Yuen J, Bergkvist L, Adami HO, Hoover R, Schairer C. Combined oestrogen-progestogen replacement therapy and breast cancer risk. Lancet 1992;340:1044.
11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350: 1047-59.
12. Mack TM. Cancer Surveillance Program in Los Angeles County. Natl Cancer Inst Monogr 1977;47:99-101.
13. Seiftert JE, Price WT, Gordon B. The California Tumor Registry: a state-of-the-art model for a regionalized, automated, population-based registry. Top Health Rec Manage 1990; 11:59-73.
14. Pike MC, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 1998;147: 718-21.
15. Breslow NE, Day NE. The analysis of case-control studies. In: Statistical methods in cancer research. Vol. 1. Lyon (France); IARC Sci Publ No. 32; 1980. p. 248-79.
16. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Eng J Med 1995;332:1589-93.
17. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer [published erratum appears in JAMA 1991;266:1362]. JAMA 1991;265:1985-90.
18. Pike MC, Bernstein L, Spicer DV. The relationship of exogenous hormones and to breast cancer risk. In: Niederhuber JE. editor. Current therapy in oncology. Philadelphia (PA): Mosby Year Book; 1995. p. 293-303.
19. Ross RK, Bernstein L. Why can't we prove that hormone replacement therapy causes breast cancer? Methodologic and biological changes. In: Proceedings of conference: HRT and breast cancer, Royal Society of Medicine, 1991. London (U.K.): Parthenon Publishing; 1992. p. 241-51.
20. Gambrell RD Jr. Clinical use of progestins in the menopausal patient: dosage and duration. J Reprod Med 1982;27(8 Suppl):531-8.
21. Oza AM, Boyd NF. Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993;15:196-208.
22. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewwod O, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal estrogen/progestin interventions (PEPI) investigators. Ann Intern Med 1999;130(4 Pt 1): 262-9.
23. Nardulli AM, Greene GL, O'Malley BW, Katzenellenbogen BS. Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology 1988;122:935-44.
24. Ross RK, Pike MC, Henderson BE, Mack TM, Lobo RA. Stroke prevention and oestrogen replacement therapy. Lancet 1989;1:505.
25. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8.